Cancer

Deep Dive

The promise and pitfalls of molecular testing in oncology

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients.

News

GSK scores major trial win with potential multiple myeloma b...

GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma.

News

AZ's immunotherapy combo misses the mark in untreated lung c...

AstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival compared with standard chemotherapy in a phase 3 tria

Views & Analysis

NICE’s track record in cancer drugs: the impact of the CDF a...

Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.

News

FDA approves Roche's "tumour agnostic" drug Rozlytrek

The FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in cancer, instead of where the disease originates. <

News